Physician profile
Tolvert E Fowler
NPI 1881805307
$1,775.66
in general payments reported to CMS, 2019-2025
15 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.85 · 2022: $249 · 2023: $607 · 2024: $448 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,497.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $554.77 | 2022-2025 | |
| Novo Nordisk INC | $350.75 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $264.78 | 2022-2025 | Zepbound, Mounjaro, Kisunla |
| Smith+Nephew, INC. | $135.55 | 2024 | Collagenase Santyl, Versajet, Grafix Pl |
| Pfizer INC. | $99.46 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $82.85 | 2023-2025 | Spravato, Xarelto |
| Astellas Pharma US INC | $80.57 | 2023-2025 | Veozah |
| Astrazeneca Pharmaceuticals Lp | $62.83 | 2022-2024 | Airsupra, Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $32.97 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $28.28 | 2022 | |
| Medtronic, INC. | $17.57 | 2023 | Intellis Adaptivestim |
| Dexcom, INC. | $17.00 | 2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $16.27 | 2024 | Freestyle Libre 3 |
| Amgen INC. | $16.02 | 2022 | |
| Bioventus LLC | $15.99 | 2024 | Supartz Fx Sodium Hyaluronate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tolvert Fowler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.